VIP and irritable bowel syndrome: In perspective, we could apply our methodology to investigate whether RLX-2 is able to prevent the increase in cell infiltrates consisting of eosinophils and the decrease in SP and VIP expressions reported in the colon of animal models (Traini et al., 2017; Traini et al., 2021) that mimic the most common intestinal morpho-functional disease, irritable bowel syndrome.